Ron Waksman

Showing 1-20 of 37 articles

Entrapment of the Impella heart pump in the mitral subvalvular apparatus

Khalid N, Shlofmitz E, Case B, Waksman R

February 5, 2021 | 10.4244/EIJ-D-19-00942

Adverse events with orbital atherectomy: an analytic review of the MAUDE database

Khalid N, Javed H, Rogers T, Hashim H, Shlofmitz E, Wermers J, Chen Y, Musallam A, Khan J, Torguson R, Bernardo N, Waksman R

July 17, 2020 | 10.4244/EIJ-D-19-00295

Bioresorbable scaffolds: did we jump the gun?

Waksman R, Forrestal B

June 12, 2020 | 10.4244/EIJV16I2A16

Coronary interventions

Chordae Tendineae Rupture and Iatrogenic Severe Mitral Regurgitation Related to Impella

Khalid N, Shlofmitz E, Case B, Waksman R

February 18, 2020 | 10.4244/EIJ-D-19-00942

Coronary interventions

Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial

Haude M, Ince H, Toelg R, Lemos P, von Birgelen C, Christiansen E, Wijns W, Neumann F, Eeckhout E, Garcia-Garcia H, Waksman R

February 7, 2020 | 10.4244/EIJ-D-18-01000

Coronary interventions

BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months

Saito S, Toelg R, Witzenbichler B, Haude M, Masotti M, Salmeron R, Witkowski A, Uematsu M, Takahashi A, Waksman R, Slagboom T

December 6, 2019 | 10.4244/EIJ-D-18-01214

Reply to the letter to the editor “Impella device use in high-risk PCI”

Khalid N, Rogers T, Shlofmitz E, Chen Y, Waksman R

October 18, 2019 | 10.4244/EIJ-D-19-00279R

Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall

Dan K, Garcia-Garcia H, Hideo-Kajita A, Zhang C, Wermers J, Kolm P, Torguson R, Waksman R

July 19, 2019 | 10.4244/EIJV15I4A59

Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall

Dan K, Garcia-Garcia H, Hideo-Kajita A, Zhang C, Wermers J, Kolm P, Torguson R, Waksman R

June 13, 2019 | 10.4244/EIJY19M06_1

Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database

Khalid N, Rogers T, Shlofmitz E, Chen Y, Khan J, Musallam A, Iantorno M, Waksman R

May 20, 2019 | 10.4244/EIJ-D-18-01021

Comparison of acute thrombogenicity for magnesium versus stainless steel stents in a porcine arteriovenous shunt model

Lipinski M, Acampado E, Cheng Q, Adams L, Torii S, Gai J, Torguson R, Hellinga DG, Joner M, Harder C, Zumstein P, Finn A, Kolodgie F, Virmani R, Waksman R

January 18, 2019 | 10.4244/EIJ-D-17-00958

Stents and scaffolds

Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds

Joner M, Ruppelt P, Zumstein P, Lapointe-Corriveau C, Leclerc G, Bulin A, Castellanos M, Wittchow E, Haude M, Waksman R

October 12, 2018 | 10.4244/EIJ-D-17-00708

Coronary interventions

Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III

Haude M, Ince H, Kische S, Abizaid A, Toelg R, Lemos P, Van Mieghem N, Verheye S, von Birgelen C, Christiansen E, Wijns W, Garcia-Garcia H, Waksman R

July 20, 2017 | 10.4244/EIJ-D-17-00254

Coronary interventions

Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model

Waksman R, Zumstein P, Pritsch M, Wittchow E, Haude M, Lapointe-Corriveau C, Leclerc G, Joner M

July 20, 2017 | 10.4244/EIJ-D-16-00915

Coronary interventions

Does acute coronary syndrome impact on the incidence of thrombosis after the implantation of an Absorb bioresorbable vascular scaffold?

Sotomi Y, Miyazaki Y, Collet C, Asano T, Suwannasom P, Thijssen J, de Winter R, Waksman R, Lipinski M, Onuma Y, Serruys P

March 20, 2017 | 10.4244/EIJ-D-16-00472

Coronary interventions

Chipping of calcified plaques by orbital atherectomy systems, but holding approval tight: is the FDA moving faster than the European CE agency? A North American perspective

Waksman R, Garcia-Garcia H

October 20, 2016 | 10.4244/EIJV12I9A178

Coronary interventions

Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016

Fajadet J, Haude M, Joner M, Koolen J, Lee M, Tölg R, Waksman R

September 18, 2016 | 10.4244/EIJV12I7A137

Coronary interventions

Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial

Haude M, Erbel R, Erne P, Verheye S, Degen H, Vermeersch P, Weissman N, Prati F, Bruining N, Waksman R, Koolen J

June 10, 2016 | 10.4244/EIJ-D-15-00371

Interventions for valvular disease

The adjunctive use of Angio-Seal in femoral vascular closure following percutaneous transcatheter aortic valve replacement

Kiramijyan S, Magalhaes M, Ben-Dor I, Koifman E, Escarcega R, Baker N, Torguson R, Okubagzi P, Bernardo N, Satler L, Pichard A, Waksman R

May 16, 2016 | 10.4244/EIJV12I1A16

The effect of complete percutaneous revascularisation with and without intravascular ultrasound guidance in the drug-eluting stent era

Magalhaes M, Minha S, Torguson R, Baker N, Escarcega R, Al Fazir O, Lipinski M, Chen F, Suddath W, Satler L, Pichard A, Waksman R

October 20, 2015 | 10.4244/EIJV11I6A124

Latest news

NEW ISSUE

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

Ahead of Print

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

March 2, 2021

Editorial

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

March 2, 2021

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

JAA

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...